Tom Powles/X
Feb 16, 2025, 04:58
Tom Powles: TROPICS4 – sacituzimab govitecan vs chemo in pretreated urothelial carcinoma
Tom Powles, Professor at the University of London, shared a post on X:
“TROPICS4 sacituzimab govitecan vs chemo in pretreated UC Annals of Oncology OS & PFS HRs=0.86.
RR 23 vs 14, but G3+ TRAE 67 vs 35% with G5 TRD. While there is activity the tox & lower RR compared to EV/erda was problematic.
Phase 2 Data on 2 other TROP2/TOPO1 ADCs.”
Shilpa Gupta, Director of Genitourinary Oncology and a Professor of Medicine at Cleveland Clinic, reshared the post on X, adding:
“Congrats Tom Powles, Petros Grivas, Andrea Necchi & entire TROPICS-04 team on getting the data out in Annals of Oncology.
It is crucial to learn from negative trials & important lessons were learned from this.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 17, 2025, 16:34
Apr 17, 2025, 16:21
Apr 17, 2025, 16:13